Abstract:

Objective Pertuzumab（P）has been recommended as the first choice of neoadjuvant treat⁃ ment for the patients with human epidermal growth factor receptor 2（HER⁃2）positive breast cancer. There are few reports on real⁃world data in China nowadays. This study aims at investigating the clinical effects of the combination therapy based on pertuzumab in patients with HER⁃2 positive breast cancer. Methods From March 2019 to January 2022，there were 60 patients with HER⁃2 positive breast cancer who received neoadjuvant treatment with pertuzumab and underwent surgery from the Guangdong Hospital of Traditional Chinese Medicine. During the neoadjuvant treatment，We evaluated the clinical effects and postoperative pathology by magnetic resonance imaging orcomputed tomography andthe Miler⁃Payne standard. Which we used to analyze the clinical effects and adverse reaction of the combination therapy based on pertuzumab in HER⁃2 positive breast cancer patients. Results Of the 60 patients who were enrolled，the overall response rete（ORR）was 82%，the pathological effective rate（G3 + G4 + G5）was 90%，and the pathological complete response rate（pCR/G5）was 53%（32/60）. Epirubicin（e）combined with cyclophosphamide（c）sequential docetaxel（T）chemotherapy group hasthe highest pCR rate，56%（18/32）. No serious event was observed during the treatment. Conclusion In the real world，the neoadjuvant therapy combined⁃ with pertuzumab for HER⁃2 positive breast cancer patientsis safe and effective，especially combined anthracycline containing chemotherapy.

Key words:

breast cancer, human epidermal growth factor receptor, neoadjuvant therapy, Pertuzumab